Home2020-01-20T09:17:26-05:00

– Our Platform

An innovative, targeted approach to treating cancer

Our treatment specifically targets unique features of cancer cells, including externalized phosphatidylserine and tumor cell lysosomes by utilizing a small lysosomal protein known as Saposin C.

Learn More

– Our Pipeline

A Pipeline-in-a-Product asset with potential for multiple indications

BXQ-350 is the foundation of our pipeline. Early clinical results have shown a strong safety and tolerability profile.

Learn More

– clinical trials

Update

Our clinical trials are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.

Learn More

Resources

Bexion Resources

Resources

Learn More
View All Resources

News

    Press Release

    Bexion Pharmaceuticals Presenting BXQ-350 Data at ASCO 2020

    May 13, 2020

    For Immediate Release, Covington, KY May 13, 2020 Bexion Pharmaceuticals announced today that the following three abstracts submitted to the 2020 American Society of Clinical Oncology (ASCO) have been accepted for oral or poster presentation: Oral Presentation Tolerability and preliminary efficacy of BXQ-350 for refractory solid tumors and high-grade gliomas: First-in-human, first-in-class phase I trial. ... Read More

      Press Release

      Bexion Pharmaceuticals Receives Orphan Drug Designation for BXQ-350 for Malignant Glioma from FDA

      May 6, 2020

      FOR IMMEDIATE RELEASE [Covington, KY May 6, 2020] Bexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug Designation for its proprietary drug, BXQ-350, for the treatment of malignant glioma, including diffuse intrinsic pontine glioma (DIPG). DIPG primarily affects children, with most diagnoses occurring between 5 ... Read More

      View All Media